Cladribine
Cladribine is listed in the FDA National Drug Code directory with 19 NDC codes, marketed under brand names including Cladribine, Mavenclad. Available dosage forms: powder, tablet, injection, solution, injection.
Drug details
- Generic Name
- Cladribine
- Brand Names
- Cladribine, Mavenclad
- Application Number
- ANDA218425
- Sponsor
- Reliable Biopharmaceutical LLC
- NDC Codes
- 19
- Dosage Forms
- POWDER, TABLET, INJECTION, SOLUTION, INJECTION
- Routes
- ORAL, INTRAVENOUS
- Active Ingredients
- CLADRIBINE
Indications and Usage
1 INDICATIONS AND USAGE Cladribine is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Because of its safety profile, use of cladribine is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, an alternate drug indicated for the treatment of MS [see Warnings and Precautions (5) ]. Cladribine is a purine antimetabolite indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Because of its safety profile, use of cladribine is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, an alternate drug indicated for the treatment of MS. ( 1 , 5 ) Limitations of Use Cladribine is not recommended for use in patients with clinically isolated syndrome (CIS) because of its safety profile . ( 1 , 5 ) Limitations of Use Cladribine is not recommended for use in patients with clinically isolated syndrome (CIS) because of its safety profile [see Warnings and Precautions (5) ].